1,482
Participants
Start Date
January 31, 2013
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
MK-8237 tablets
MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
Placebo tablets
Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
Rescue Medication: Self-Injectable Epinephrine
Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
Rescue Medication: Loratadine tablets
Loratadine tablet 10 mg administered orally as needed for rescue medication.
Rescue Medication: Olopatadine ophthalmic drops
Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
Rescue Medication: Mometasone furoate nasal spray
Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
Merck Sharp & Dohme LLC
INDUSTRY
ALK-Abelló A/S
INDUSTRY